On April 15, 2010, PR Newswire reported that MedClean Technologies, Inc. (MCLN) and Verde Enterprises LLC executed a distribution agreement to provide on-site integrated medical waste disposal and document destruction services. The intent of the agreement is to pave a path for both companies to collaborate and serve approximately 250 large-quantity medical waste generators in New York and New Jersey in hopes of producing approximately $2 million in new business. I checked the MCLN website this morning, but the PR News release was not yet posted.
Here is an updated recap of MCLN’s recent strategic developments.
- Distributorship with Verde Enterprises
- Distributorship with Barnett Medical Services
- Partnership with Salesconx
- The launch of MedClean’s MC4100/MC4200 products
- Co-marketing agreement with Green Umbrella Solutions
- Record 2009 Financial Results
This news release served to further solidify my belief in MCLN and their ability to increase their share price over the next year or so. While the alliances are critical to the successes of MCLN, they only represent one side of the coin. Unless MCLN substantiates their claims with actual sales, the millions of dollars generated by the proposed new business represent nothing more than dreams expressed in written words.
Remember, since MCLN is a penny stock it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your Buy/Sell decisions on the opinions and comments of LA Stock Talk.
Disclosure: LA Long MCLN
Thursday, April 15, 2010
Wednesday, April 14, 2010
CRXX: CombinatoRx
Business Wire reported that according to the Journal of the American Society of Hematology article entitled, "Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies," Rickles, et.al., Blood First Edition Paper, prepublished online April 9, 2010; DOI 10.1182/blood-2009-11-252668, CombinatoRx (CRXX) researchers in collaboration with Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, demonstrated that the exposure of the large B-cell lymphoma cell lines to A2A agonists and specific PDE inhibitors resulted in rapid synergistic inhibition of proliferation and induction of apoptosis. Which I loosely interpret to mean cell death in cancer cells (induction of apoptosis) and stopping the spread of cancer cells (inhibition of proliferation).
Currently, CRXX is above both its 50 day and 200 day moving averages of $1.27 and $1.19 respectively and opened with a gap on April 14, 2010 at $1.48 after a previous day close of $1.33. Does this mean that CRXX is going to experience some earth shaking success in the near future?
Below is some information on three of the products in the CRXX pipeline that I obtained from their website and news releases:
Exalgo ™: the FDA approved the New Drug Application (NDA) for Exalgo ™ extended release tablets on March 1, 2010 which triggered a $40 million milestone payment to CombinatoRx from Covidien and a 44% increase in the share price of CRXX before the opening bell. Covidien acquired the commercial rights to Exalgo ™ in June 2009 and has responsibility for all marketing and sales of the product in the United States. CRXX is eligible to receive tiered royalties on net sales of Exalgo ™.
Prednisporin™ is a topical ocular drug for the treatment of flammatory ocular diseases such as conjunctivitis which CominatoRx has exclusively licensed to Fovea Pharmaceuticals. In 2009, Fovea conducted a Phase 2a proof-of-concept clinical trial in the United States in approximately 150 patients and reported no adverse events.
CRx-102 (Synavive™) is intended to selectively amplify the potent immuno-modulatory activity of steroids, with reduced side effects, also known as a dissociated steroid. The market potential consists of an estimated 33 million osteoarthritis patients and 2 million rheumatoid arthritis patients in the United States. CRXX has completed a phase 2 study in knee osteoarthis with no serious adverse events reported from patients. The phase 2 hand study demonstrated statistically significant improvement in pain compared to the placebo.
After I considered the above information, the initiated coverage of CRXX by Liberty Analytics Co., the company’s YTD Price Performance of +60.2%, the $0.15 gap up this morning at $1.48 and a 52 week high of $2.60 on September 16, 2009, I wonder if their potential for earth shaking success could be a tsunami in the making. I’ve decided to hang on to my shares and ride out the wave.
Remember that since CRXX is a penny stock, it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. It is important to do your own Due Diligence before investing your money in this or any other stock and do not base your buy/sell decisions on the opinions and comments of LA Stock Talk.
LA
Currently, CRXX is above both its 50 day and 200 day moving averages of $1.27 and $1.19 respectively and opened with a gap on April 14, 2010 at $1.48 after a previous day close of $1.33. Does this mean that CRXX is going to experience some earth shaking success in the near future?
Below is some information on three of the products in the CRXX pipeline that I obtained from their website and news releases:
Exalgo ™: the FDA approved the New Drug Application (NDA) for Exalgo ™ extended release tablets on March 1, 2010 which triggered a $40 million milestone payment to CombinatoRx from Covidien and a 44% increase in the share price of CRXX before the opening bell. Covidien acquired the commercial rights to Exalgo ™ in June 2009 and has responsibility for all marketing and sales of the product in the United States. CRXX is eligible to receive tiered royalties on net sales of Exalgo ™.
Prednisporin™ is a topical ocular drug for the treatment of flammatory ocular diseases such as conjunctivitis which CominatoRx has exclusively licensed to Fovea Pharmaceuticals. In 2009, Fovea conducted a Phase 2a proof-of-concept clinical trial in the United States in approximately 150 patients and reported no adverse events.
CRx-102 (Synavive™) is intended to selectively amplify the potent immuno-modulatory activity of steroids, with reduced side effects, also known as a dissociated steroid. The market potential consists of an estimated 33 million osteoarthritis patients and 2 million rheumatoid arthritis patients in the United States. CRXX has completed a phase 2 study in knee osteoarthis with no serious adverse events reported from patients. The phase 2 hand study demonstrated statistically significant improvement in pain compared to the placebo.
After I considered the above information, the initiated coverage of CRXX by Liberty Analytics Co., the company’s YTD Price Performance of +60.2%, the $0.15 gap up this morning at $1.48 and a 52 week high of $2.60 on September 16, 2009, I wonder if their potential for earth shaking success could be a tsunami in the making. I’ve decided to hang on to my shares and ride out the wave.
Remember that since CRXX is a penny stock, it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. It is important to do your own Due Diligence before investing your money in this or any other stock and do not base your buy/sell decisions on the opinions and comments of LA Stock Talk.
LA
Tuesday, April 13, 2010
Update: MCLN - MedClean Technologies
On April 13, 2010, PR Newswire reported that MedClean Technologies, Inc. (MCLN) and Barnett Medical Services (Barnett) signed a distributor agreement to synergize the service portfolio of both firms and to target the more than 230 large quantity medical waste generators and 1,500 medium quantity medical waste generators throughout the four western states currently served by Barnett. Brett Espicha, President and CEO of Barnett said the new alliance provides them with a “cradle-to-grave” medical waste disposal service, an opportunity for both firms to achieve expected revenues of $1MM to $2MM in the first year and lays the ground work for a 10 percent market penetration prospectively.
The alliance with Barnett is one of the many recent strategic puzzle pieces Mr. Laky, President and CEO of MCLN, has pulled together to enable them to achieve their 100% compounded annual growth rate target over the next five years.
Recent Strategic Developments for MCLN
- Distributorship with Barnett Medical Services
- Partnership with Salesconx
- The launch of MedClean’s MC4100/MC4200 products
- Co-marketing agreement with Green Umbrella Solutions
- Record 2009 Financial Results
I am of the opinion that MCLN has the potential to increase their share price over the next year or so, however, since MCLN is a penny stock, it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your buy/sell decisions on the opinions and comments of LA Stock Talk.
LA
Disclosure: LA Long MCLN
The alliance with Barnett is one of the many recent strategic puzzle pieces Mr. Laky, President and CEO of MCLN, has pulled together to enable them to achieve their 100% compounded annual growth rate target over the next five years.
Recent Strategic Developments for MCLN
- Distributorship with Barnett Medical Services
- Partnership with Salesconx
- The launch of MedClean’s MC4100/MC4200 products
- Co-marketing agreement with Green Umbrella Solutions
- Record 2009 Financial Results
I am of the opinion that MCLN has the potential to increase their share price over the next year or so, however, since MCLN is a penny stock, it is a risky investment and the price of the stock is subject to rapid fire up/down fluctuations. Remember the importance of doing your own Due Diligence before investing your money in this or any other stock and do not base your buy/sell decisions on the opinions and comments of LA Stock Talk.
LA
Disclosure: LA Long MCLN
Friday, April 9, 2010
VIAP: VIA Pharmaceuticals, Inc
Shares of VIA Pharmaceuticals, Inc (VIAP) have been toggling back and forth around $0.15 and $0.20 for the last few months. As noted on their website, their main product, VIA-2291, is an important mediator of information involved in the development and progression of atherosclerosis; VIA holds exclusive worldwide rights to develop and commercialize their product.
VIA-2291 is currently being studied in three Phase 2 clinical designed with the intent of providing proof-of-concept as early as possible in the clinical development process. While the initial plan is to target the secondary prevention market for existing adverse cardiac event patients, the product has the potential to benefit the 15 million people who suffer from atherosclerosis and cardio vascular disease. At this point, VIA-2291 is Phase III ready.
In a March 31, 2010 PR news release, VIAP announced a 63% reduction in their workforce to approximately 6 people in the business development and financial areas. This strategic move seems to be a step in the right direction since it significantly reduces over head and directs their existing funds towards core research and development.
VIA-2291 is currently being studied in three Phase 2 clinical designed with the intent of providing proof-of-concept as early as possible in the clinical development process. While the initial plan is to target the secondary prevention market for existing adverse cardiac event patients, the product has the potential to benefit the 15 million people who suffer from atherosclerosis and cardio vascular disease. At this point, VIA-2291 is Phase III ready.
In a March 31, 2010 PR news release, VIAP announced a 63% reduction in their workforce to approximately 6 people in the business development and financial areas. This strategic move seems to be a step in the right direction since it significantly reduces over head and directs their existing funds towards core research and development.
Tuesday, April 6, 2010
MedClean Technologies (MCLN.OB)
MedClean Technologies, Inc, (MCLN.OB) formerly Aduromed Industries, Inc, is in the business of providing solutions for managing medical waste on site.
According to several press releases in March 2010, the company announced a partnership with Salesconx to deploy a 15 person national medical technology sales force to launch their new MC4100/MC4200 product line and a co-marketing agreement with Green Umbrella Solutions, a premier provider of services and technology for the destruction of Hippa documents. Both of these strategic alignments, according to Dave Laky, President and CEO, MedClean Technologies, Inc, lay the ground work for them to reach their objective of 100% compounded annual growth over the next five years.
The market for medical waste treatment is delineated by customer size: Large Quantity Generators (“LQGs”), those who generate large volumes of medical waste (in excess of 100,000 pounds annually), and Small Quantity Generators (“SQGs”), (those who generate less than 100,000 pounds annually).
According to several press releases in March 2010, the company announced a partnership with Salesconx to deploy a 15 person national medical technology sales force to launch their new MC4100/MC4200 product line and a co-marketing agreement with Green Umbrella Solutions, a premier provider of services and technology for the destruction of Hippa documents. Both of these strategic alignments, according to Dave Laky, President and CEO, MedClean Technologies, Inc, lay the ground work for them to reach their objective of 100% compounded annual growth over the next five years.
The market for medical waste treatment is delineated by customer size: Large Quantity Generators (“LQGs”), those who generate large volumes of medical waste (in excess of 100,000 pounds annually), and Small Quantity Generators (“SQGs”), (those who generate less than 100,000 pounds annually).
Subscribe to:
Posts (Atom)